Impact of HPV vaccination on HPV-related oral infections

•Lower HPV16/18 prevalence among women recipients of two or three HPV vaccine doses.•One HPV vaccine dose may be less efficient in preventing oral HPV infection.•No difference was observed between one dose vaccinated and unvaccinated women. Human papillomavirus (HPV) is one of the most common sexual...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2023-01, Vol.136, p.106244-106244, Article 106244
Hauptverfasser: Gheit, Tarik, Muwonge, Richard, Lucas, Eric, Galati, Luisa, Anantharaman, Devasena, McKay-Chopin, Sandrine, Malvi, Sylla G, Jayant, Kasturi, Joshi, Smita, Esmy, Pulikkottil O, Pillai, M Radhakrishna, Basu, Partha, Sankaranarayanan, Rengaswamy, Tommasino, Massimo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106244
container_issue
container_start_page 106244
container_title Oral oncology
container_volume 136
creator Gheit, Tarik
Muwonge, Richard
Lucas, Eric
Galati, Luisa
Anantharaman, Devasena
McKay-Chopin, Sandrine
Malvi, Sylla G
Jayant, Kasturi
Joshi, Smita
Esmy, Pulikkottil O
Pillai, M Radhakrishna
Basu, Partha
Sankaranarayanan, Rengaswamy
Tommasino, Massimo
description •Lower HPV16/18 prevalence among women recipients of two or three HPV vaccine doses.•One HPV vaccine dose may be less efficient in preventing oral HPV infection.•No difference was observed between one dose vaccinated and unvaccinated women. Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Although the efficacy of the HPV vaccine in preventing the development of cervical pre-malignant lesions has been well demonstrated, the efficacy of the HPV vaccine in preventing HPV infection in the upper respiratory tract has been poorly studied. In the context of the IARC cohort study of two versus three doses of HPV vaccine in India, we compared the HPV type prevalence in the oral cavity of women vaccinated with three doses, two doses, or a single dose of quadrivalent HPV vaccine with that of unvaccinated women. A total of 997 oral samples, from 818 vaccinated women and 179 unvaccinated women, were collected at three study sites. All the participants were sexually active at the time of sample collection. The age-standardized proportion (ASP) of HPV16/18 infections was 2.0 % (95 % CI, 1.0–3.0 %) in vaccinated women and 4.2 % (95 % CI, 1.2–7.2 %) in unvaccinated women. HPV16 was detected in 3.5 % of single-dose recipients, 1.2 % of two-dose recipients (days 1 and 180), and 1.5 % of three-dose recipients (days 1, 60, and 180), whereas 3.3 % of the unvaccinated women tested positive for HPV16. The same trend was observed for HPV18. Our findings agree with those of previous studies on the efficacy of HPV vaccination in reducing oral HPV infections and provide indications that a single vaccine dose may be less efficient than two or three doses in preventing oral HPV infection.
doi_str_mv 10.1016/j.oraloncology.2022.106244
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9833124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837522005346</els_id><sourcerecordid>2738188961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-4710b44fc177e29754f6b6e2617a61af4576b04d659cab0fa79a6360a8c6725b3</originalsourceid><addsrcrecordid>eNqNkEtLAzEUhYMotlb_ggyu3EzNOxkXgtRHCwVdqNuQyWRqynRSk2mh_96U1qI7IZCQc-45lw-AKwSHCCJ-Mx_6oBvfGt_42WaIIcZJ4JjSI9BHUhQ5ZAU5Tm_CZS6JYD1wFuMcQsgQg6egRziFGDLWB3KyWGrTZb7Oxq8f2Vob41rdOd9m6aSvPNhGd7bKtp2Za2trtmo8Bye1bqK92N8D8P70-DYa59OX58nofpobKkWXU4FgSWltkBAWF4LRmpfcYo6E5kjXlAleQlpxVhhdwlqLQnPCoZaGC8xKMgB3u9zlqlzYyti2S4uoZXALHTbKa6f-Kq37VDO_VoUkBGGaAq73AcF_rWzs1MJFY5tGt9avosKCSCRlwVGy3u6sJvgYg60PNQiqLXo1V7_Rqy16tUOfhi9_L3oY_WGdDA87g0241s4GFY2zrbGVCwmqqrz7T883yMmbxA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2738188961</pqid></control><display><type>article</type><title>Impact of HPV vaccination on HPV-related oral infections</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gheit, Tarik ; Muwonge, Richard ; Lucas, Eric ; Galati, Luisa ; Anantharaman, Devasena ; McKay-Chopin, Sandrine ; Malvi, Sylla G ; Jayant, Kasturi ; Joshi, Smita ; Esmy, Pulikkottil O ; Pillai, M Radhakrishna ; Basu, Partha ; Sankaranarayanan, Rengaswamy ; Tommasino, Massimo</creator><creatorcontrib>Gheit, Tarik ; Muwonge, Richard ; Lucas, Eric ; Galati, Luisa ; Anantharaman, Devasena ; McKay-Chopin, Sandrine ; Malvi, Sylla G ; Jayant, Kasturi ; Joshi, Smita ; Esmy, Pulikkottil O ; Pillai, M Radhakrishna ; Basu, Partha ; Sankaranarayanan, Rengaswamy ; Tommasino, Massimo</creatorcontrib><description>•Lower HPV16/18 prevalence among women recipients of two or three HPV vaccine doses.•One HPV vaccine dose may be less efficient in preventing oral HPV infection.•No difference was observed between one dose vaccinated and unvaccinated women. Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Although the efficacy of the HPV vaccine in preventing the development of cervical pre-malignant lesions has been well demonstrated, the efficacy of the HPV vaccine in preventing HPV infection in the upper respiratory tract has been poorly studied. In the context of the IARC cohort study of two versus three doses of HPV vaccine in India, we compared the HPV type prevalence in the oral cavity of women vaccinated with three doses, two doses, or a single dose of quadrivalent HPV vaccine with that of unvaccinated women. A total of 997 oral samples, from 818 vaccinated women and 179 unvaccinated women, were collected at three study sites. All the participants were sexually active at the time of sample collection. The age-standardized proportion (ASP) of HPV16/18 infections was 2.0 % (95 % CI, 1.0–3.0 %) in vaccinated women and 4.2 % (95 % CI, 1.2–7.2 %) in unvaccinated women. HPV16 was detected in 3.5 % of single-dose recipients, 1.2 % of two-dose recipients (days 1 and 180), and 1.5 % of three-dose recipients (days 1, 60, and 180), whereas 3.3 % of the unvaccinated women tested positive for HPV16. The same trend was observed for HPV18. Our findings agree with those of previous studies on the efficacy of HPV vaccination in reducing oral HPV infections and provide indications that a single vaccine dose may be less efficient than two or three doses in preventing oral HPV infection.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2022.106244</identifier><identifier>PMID: 36402055</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cervical cancer ; Cohort Studies ; Female ; Head and neck cancers ; HPV genotyping ; HPV vaccine ; Human papillomavirus 16 ; Human papillomavirus 18 ; Human Papillomavirus Viruses ; Humans ; India ; Oral cavity ; Papillomavirus ; Papillomavirus Infections ; Papillomavirus Vaccines ; Upper respiratory tract ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - prevention &amp; control ; Vaccination</subject><ispartof>Oral oncology, 2023-01, Vol.136, p.106244-106244, Article 106244</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Ltd.</rights><rights>2022 Published by Elsevier Ltd. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-4710b44fc177e29754f6b6e2617a61af4576b04d659cab0fa79a6360a8c6725b3</citedby><cites>FETCH-LOGICAL-c487t-4710b44fc177e29754f6b6e2617a61af4576b04d659cab0fa79a6360a8c6725b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.oraloncology.2022.106244$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36402055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gheit, Tarik</creatorcontrib><creatorcontrib>Muwonge, Richard</creatorcontrib><creatorcontrib>Lucas, Eric</creatorcontrib><creatorcontrib>Galati, Luisa</creatorcontrib><creatorcontrib>Anantharaman, Devasena</creatorcontrib><creatorcontrib>McKay-Chopin, Sandrine</creatorcontrib><creatorcontrib>Malvi, Sylla G</creatorcontrib><creatorcontrib>Jayant, Kasturi</creatorcontrib><creatorcontrib>Joshi, Smita</creatorcontrib><creatorcontrib>Esmy, Pulikkottil O</creatorcontrib><creatorcontrib>Pillai, M Radhakrishna</creatorcontrib><creatorcontrib>Basu, Partha</creatorcontrib><creatorcontrib>Sankaranarayanan, Rengaswamy</creatorcontrib><creatorcontrib>Tommasino, Massimo</creatorcontrib><title>Impact of HPV vaccination on HPV-related oral infections</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>•Lower HPV16/18 prevalence among women recipients of two or three HPV vaccine doses.•One HPV vaccine dose may be less efficient in preventing oral HPV infection.•No difference was observed between one dose vaccinated and unvaccinated women. Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Although the efficacy of the HPV vaccine in preventing the development of cervical pre-malignant lesions has been well demonstrated, the efficacy of the HPV vaccine in preventing HPV infection in the upper respiratory tract has been poorly studied. In the context of the IARC cohort study of two versus three doses of HPV vaccine in India, we compared the HPV type prevalence in the oral cavity of women vaccinated with three doses, two doses, or a single dose of quadrivalent HPV vaccine with that of unvaccinated women. A total of 997 oral samples, from 818 vaccinated women and 179 unvaccinated women, were collected at three study sites. All the participants were sexually active at the time of sample collection. The age-standardized proportion (ASP) of HPV16/18 infections was 2.0 % (95 % CI, 1.0–3.0 %) in vaccinated women and 4.2 % (95 % CI, 1.2–7.2 %) in unvaccinated women. HPV16 was detected in 3.5 % of single-dose recipients, 1.2 % of two-dose recipients (days 1 and 180), and 1.5 % of three-dose recipients (days 1, 60, and 180), whereas 3.3 % of the unvaccinated women tested positive for HPV16. The same trend was observed for HPV18. Our findings agree with those of previous studies on the efficacy of HPV vaccination in reducing oral HPV infections and provide indications that a single vaccine dose may be less efficient than two or three doses in preventing oral HPV infection.</description><subject>Cervical cancer</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Head and neck cancers</subject><subject>HPV genotyping</subject><subject>HPV vaccine</subject><subject>Human papillomavirus 16</subject><subject>Human papillomavirus 18</subject><subject>Human Papillomavirus Viruses</subject><subject>Humans</subject><subject>India</subject><subject>Oral cavity</subject><subject>Papillomavirus</subject><subject>Papillomavirus Infections</subject><subject>Papillomavirus Vaccines</subject><subject>Upper respiratory tract</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - prevention &amp; control</subject><subject>Vaccination</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEtLAzEUhYMotlb_ggyu3EzNOxkXgtRHCwVdqNuQyWRqynRSk2mh_96U1qI7IZCQc-45lw-AKwSHCCJ-Mx_6oBvfGt_42WaIIcZJ4JjSI9BHUhQ5ZAU5Tm_CZS6JYD1wFuMcQsgQg6egRziFGDLWB3KyWGrTZb7Oxq8f2Vob41rdOd9m6aSvPNhGd7bKtp2Za2trtmo8Bye1bqK92N8D8P70-DYa59OX58nofpobKkWXU4FgSWltkBAWF4LRmpfcYo6E5kjXlAleQlpxVhhdwlqLQnPCoZaGC8xKMgB3u9zlqlzYyti2S4uoZXALHTbKa6f-Kq37VDO_VoUkBGGaAq73AcF_rWzs1MJFY5tGt9avosKCSCRlwVGy3u6sJvgYg60PNQiqLXo1V7_Rqy16tUOfhi9_L3oY_WGdDA87g0241s4GFY2zrbGVCwmqqrz7T883yMmbxA</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Gheit, Tarik</creator><creator>Muwonge, Richard</creator><creator>Lucas, Eric</creator><creator>Galati, Luisa</creator><creator>Anantharaman, Devasena</creator><creator>McKay-Chopin, Sandrine</creator><creator>Malvi, Sylla G</creator><creator>Jayant, Kasturi</creator><creator>Joshi, Smita</creator><creator>Esmy, Pulikkottil O</creator><creator>Pillai, M Radhakrishna</creator><creator>Basu, Partha</creator><creator>Sankaranarayanan, Rengaswamy</creator><creator>Tommasino, Massimo</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202301</creationdate><title>Impact of HPV vaccination on HPV-related oral infections</title><author>Gheit, Tarik ; Muwonge, Richard ; Lucas, Eric ; Galati, Luisa ; Anantharaman, Devasena ; McKay-Chopin, Sandrine ; Malvi, Sylla G ; Jayant, Kasturi ; Joshi, Smita ; Esmy, Pulikkottil O ; Pillai, M Radhakrishna ; Basu, Partha ; Sankaranarayanan, Rengaswamy ; Tommasino, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-4710b44fc177e29754f6b6e2617a61af4576b04d659cab0fa79a6360a8c6725b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cervical cancer</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Head and neck cancers</topic><topic>HPV genotyping</topic><topic>HPV vaccine</topic><topic>Human papillomavirus 16</topic><topic>Human papillomavirus 18</topic><topic>Human Papillomavirus Viruses</topic><topic>Humans</topic><topic>India</topic><topic>Oral cavity</topic><topic>Papillomavirus</topic><topic>Papillomavirus Infections</topic><topic>Papillomavirus Vaccines</topic><topic>Upper respiratory tract</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - prevention &amp; control</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gheit, Tarik</creatorcontrib><creatorcontrib>Muwonge, Richard</creatorcontrib><creatorcontrib>Lucas, Eric</creatorcontrib><creatorcontrib>Galati, Luisa</creatorcontrib><creatorcontrib>Anantharaman, Devasena</creatorcontrib><creatorcontrib>McKay-Chopin, Sandrine</creatorcontrib><creatorcontrib>Malvi, Sylla G</creatorcontrib><creatorcontrib>Jayant, Kasturi</creatorcontrib><creatorcontrib>Joshi, Smita</creatorcontrib><creatorcontrib>Esmy, Pulikkottil O</creatorcontrib><creatorcontrib>Pillai, M Radhakrishna</creatorcontrib><creatorcontrib>Basu, Partha</creatorcontrib><creatorcontrib>Sankaranarayanan, Rengaswamy</creatorcontrib><creatorcontrib>Tommasino, Massimo</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gheit, Tarik</au><au>Muwonge, Richard</au><au>Lucas, Eric</au><au>Galati, Luisa</au><au>Anantharaman, Devasena</au><au>McKay-Chopin, Sandrine</au><au>Malvi, Sylla G</au><au>Jayant, Kasturi</au><au>Joshi, Smita</au><au>Esmy, Pulikkottil O</au><au>Pillai, M Radhakrishna</au><au>Basu, Partha</au><au>Sankaranarayanan, Rengaswamy</au><au>Tommasino, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of HPV vaccination on HPV-related oral infections</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2023-01</date><risdate>2023</risdate><volume>136</volume><spage>106244</spage><epage>106244</epage><pages>106244-106244</pages><artnum>106244</artnum><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>•Lower HPV16/18 prevalence among women recipients of two or three HPV vaccine doses.•One HPV vaccine dose may be less efficient in preventing oral HPV infection.•No difference was observed between one dose vaccinated and unvaccinated women. Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Although the efficacy of the HPV vaccine in preventing the development of cervical pre-malignant lesions has been well demonstrated, the efficacy of the HPV vaccine in preventing HPV infection in the upper respiratory tract has been poorly studied. In the context of the IARC cohort study of two versus three doses of HPV vaccine in India, we compared the HPV type prevalence in the oral cavity of women vaccinated with three doses, two doses, or a single dose of quadrivalent HPV vaccine with that of unvaccinated women. A total of 997 oral samples, from 818 vaccinated women and 179 unvaccinated women, were collected at three study sites. All the participants were sexually active at the time of sample collection. The age-standardized proportion (ASP) of HPV16/18 infections was 2.0 % (95 % CI, 1.0–3.0 %) in vaccinated women and 4.2 % (95 % CI, 1.2–7.2 %) in unvaccinated women. HPV16 was detected in 3.5 % of single-dose recipients, 1.2 % of two-dose recipients (days 1 and 180), and 1.5 % of three-dose recipients (days 1, 60, and 180), whereas 3.3 % of the unvaccinated women tested positive for HPV16. The same trend was observed for HPV18. Our findings agree with those of previous studies on the efficacy of HPV vaccination in reducing oral HPV infections and provide indications that a single vaccine dose may be less efficient than two or three doses in preventing oral HPV infection.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36402055</pmid><doi>10.1016/j.oraloncology.2022.106244</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1368-8375
ispartof Oral oncology, 2023-01, Vol.136, p.106244-106244, Article 106244
issn 1368-8375
1879-0593
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9833124
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Cervical cancer
Cohort Studies
Female
Head and neck cancers
HPV genotyping
HPV vaccine
Human papillomavirus 16
Human papillomavirus 18
Human Papillomavirus Viruses
Humans
India
Oral cavity
Papillomavirus
Papillomavirus Infections
Papillomavirus Vaccines
Upper respiratory tract
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - prevention & control
Vaccination
title Impact of HPV vaccination on HPV-related oral infections
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20HPV%20vaccination%20on%20HPV-related%20oral%20infections&rft.jtitle=Oral%20oncology&rft.au=Gheit,%20Tarik&rft.date=2023-01&rft.volume=136&rft.spage=106244&rft.epage=106244&rft.pages=106244-106244&rft.artnum=106244&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2022.106244&rft_dat=%3Cproquest_pubme%3E2738188961%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2738188961&rft_id=info:pmid/36402055&rft_els_id=S1368837522005346&rfr_iscdi=true